Page last updated: 2024-08-21

toyocamycin and Non-alcoholic Fatty Liver Disease

toyocamycin has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akazawa, Y; Eguchi, S; Kanda, Y; Kido, Y; Matsuda, K; Miyaaki, H; Nakao, K; Nakashima, M; Ohnita, K; Sakai, Y; Tabuchi, M; Takahara, I; Takeshima, F; Taura, N	1

Other Studies

1 other study(ies) available for toyocamycin and Non-alcoholic Fatty Liver Disease

Article	Year
Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. PloS one, 2017, Volume: 12, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cells, Cultured; Diet, High-Fat; Endoplasmic Reticulum Stress; Hepatocytes; Humans; Lipogenesis; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Rats; Rats, Wistar; Toyocamycin	2017

Article

Year

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.

PloS one, 2017, Volume: 12, Issue:3

Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cells, Cultured; Diet, High-Fat; Endoplasmic Reticulum Stress; Hepatocytes; Humans; Lipogenesis; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Rats; Rats, Wistar; Toyocamycin

2017